<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04853017</url>
  </required_header>
  <id_info>
    <org_study_id>ELI-002-001</org_study_id>
    <nct_id>NCT04853017</nct_id>
  </id_info>
  <brief_title>A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors</brief_title>
  <acronym>AMPLIFY-201</acronym>
  <official_title>First in Human Phase 1 Trial of ELI-002 Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS) Mutated Pancreatic Ductal Adenocarcinoma and Other Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elicio Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Elicio Therapeutics</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a&#xD;
      lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of&#xD;
      lipid-conjugated peptide-based antigens [Amph-Peptides]) as adjuvant treatment of minimal&#xD;
      residual disease (MRD) in subjects with KRAS/neuroblastoma ras viral oncogene homolog (NRAS)&#xD;
      mutated PDAC or other solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1 dose escalation study in which ELI-002 2P (Amph modified KRAS peptides,&#xD;
      Amph-G12D and Amph-G12R admixed with admixed Amph-CpG-7909) will be evaluated, with plans to&#xD;
      transition to the ELI-002 7P drug product containing all 7 Amph-Peptides (G12D, G12R, G12V,&#xD;
      G12A, G12C, G12S, G13D) in future clinical trials.&#xD;
&#xD;
      This is an open-label, dose-escalation, 3+3 design in which approximately 18 subjects will be&#xD;
      treated in 3 planned dose level cohorts. Increasing doses of Amph-CpG-7909 will be evaluated&#xD;
      sequentially. Safety and pharmacodynamic data will be evaluated and a recommended Phase 2&#xD;
      dose (RP2D) will be determined in consideration of a maximum tolerated dose (MTD) if&#xD;
      observed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 4, 2021</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the MTD of ELI-002 and the RP2D</measure>
    <time_frame>28 days after first dose</time_frame>
    <description>The MTD is defined as the highest dose level for which &lt;33% of subjects had a dose-limiting toxicity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the safety of ELI-002</measure>
    <time_frame>30 days after last dose</time_frame>
    <description>Safety will be assessed by the incidence of adverse events (AEs) and clinically significant laboratory tests and vital signs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the circulating tumor DNA (ctDNA) reduction and clearance rate</measure>
    <time_frame>6 months</time_frame>
    <description>The ctDNA reduction and clearance rate is defined as the reduction or clearance of ctDNA compared to baseline.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Minimal Residual Disease</condition>
  <condition>KRAS G12D</condition>
  <condition>KRAS G12R</condition>
  <condition>NRAS G12D</condition>
  <condition>NRAS G12R</condition>
  <condition>Pancreatic Ductal Adenocarcinoma</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Cholangiocarcinoma</condition>
  <condition>Bile Duct Cancer</condition>
  <condition>Gallbladder Carcinoma</condition>
  <arm_group>
    <arm_group_label>ELI-002 2P Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ELI-002 2P Amph-CpG-7909 (0.1 mg) admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosiing)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ELI-002 2P Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ELI-002 2P Amph-CpG-7909 (0.5 mg) admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosiing)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ELI-002 2P Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ELI-002 2P Amph-CpG-7909 (2.5 mg) admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosiing)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ELI-002 2P</intervention_name>
    <description>Amph-CpG-7909 admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing)</description>
    <arm_group_label>ELI-002 2P Cohort 1</arm_group_label>
    <arm_group_label>ELI-002 2P Cohort 2</arm_group_label>
    <arm_group_label>ELI-002 2P Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  KRAS/NRAS mutated (G12D or G12R) solid tumor&#xD;
&#xD;
          -  Positive for circulating tumor DNA (ctDNA) despite prior standard therapy including&#xD;
             surgery and chemotherapy/radiation therapy where applicable&#xD;
&#xD;
          -  Screening CT is negative for recurrent disease&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of tumor mutations where specific therapy is approved, and the patient is&#xD;
             able to receive the approved therapy&#xD;
&#xD;
          -  Known brain metastases&#xD;
&#xD;
          -  Use of immunosuppressive drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Trial Inquiries</last_name>
    <phone>617-714-9884</phone>
    <email>clinicaltrialinquiries@elicio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Chung, MD</last_name>
      <phone>626-218-8900</phone>
      <email>vchung@coh.org</email>
    </contact>
    <contact_backup>
      <last_name>City of Hope Clinical Trials Line</last_name>
      <phone>626-218-1133</phone>
    </contact_backup>
    <investigator>
      <last_name>Vincent Chung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Yonemoto</last_name>
      <phone>310-974-6500</phone>
    </contact>
    <investigator>
      <last_name>Zev Wainberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>McKenna Russen</last_name>
      <phone>720-848-8785</phone>
      <email>mckenna.russen@cuanschutz.edu</email>
    </contact>
    <investigator>
      <last_name>Alexis Leal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Koski</last_name>
      <phone>319-353-8155</phone>
      <email>amy-koski@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Muhammed Furqan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colin D Weekes, MD</last_name>
      <phone>617-724-4000</phone>
      <email>cdweekes@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Colin D Weekes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CTO P1 Trials</last_name>
      <email>CTOP1Trials@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Ding M Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katlyn Kraft</last_name>
      <phone>314-747-5440</phone>
      <email>katlyn.kraft@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Haeseong Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwell Health</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Craig Devoe, MD</last_name>
      <phone>516-734-8896</phone>
    </contact>
    <contact_backup>
      <email>CCTOPhase1@northwell.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Craig Devoe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Manager</last_name>
      <phone>646-888-4327</phone>
      <email>yaqubiea@mskcc.org</email>
    </contact>
    <contact_backup>
      <last_name>Eileen M O'Reilly, MD</last_name>
      <phone>646-888-4182</phone>
    </contact_backup>
    <investigator>
      <last_name>Eileen M O'Reilly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology - Centennial Clinic</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>844-482-4812</phone>
      <email>DDUReferrals@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Melissa Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mercy David</last_name>
      <phone>832-421-7290</phone>
      <email>MFDavid@mdanderson.org</email>
    </contact>
    <contact_backup>
      <last_name>Li Xu</last_name>
      <phone>713-745-2416</phone>
      <email>lixu@mdanderson.org</email>
    </contact_backup>
    <investigator>
      <last_name>Shubham Pant, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 16, 2021</study_first_submitted>
  <study_first_submitted_qc>April 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Minimal residual disease (MRD)</keyword>
  <keyword>Kirsten rat sarcoma (KRAS)</keyword>
  <keyword>Neuroblastoma ras viral oncogene homolog (NRAS)</keyword>
  <keyword>Pancreatic ductal adenocarcinoma (PDAC)</keyword>
  <keyword>Colorectal cancer (CRC)</keyword>
  <keyword>Colon cancer</keyword>
  <keyword>Rectal cancer</keyword>
  <keyword>Non-small-cell lung cancer (NSCLC)</keyword>
  <keyword>Mucinous Ovarian cancer</keyword>
  <keyword>Cholangiocarcinoma (CCA)</keyword>
  <keyword>Bile duct cancer</keyword>
  <keyword>Gallbladder carcinoma</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Vaccine therapy</keyword>
  <keyword>Adjuvant therapy</keyword>
  <keyword>circulating tumor DNA (ctDNA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Neoplasm, Residual</mesh_term>
    <mesh_term>Bile Duct Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

